Navigation Links
New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response
Date:11/7/2011

BRUSSELS and CHICAGO, Nov. 7, 2011 /PRNewswire/ -- UCB today announced findings from a post-hoc analysis suggesting that disease activity response rates to Cimzia® (certolizumab pegol) plus methotrexate (MTX) as early as Week 12 helped predict the effect on structural joint damage in patients with moderate to severe rheumatoid arthritis (RA) at one year. Comparable responses were found by both RAPID3 (Routine Assessment of Patient Index Data 3) and EULAR (European League Against Rheumatism), suggesting that either response criteria could be used as predictors of structural joint damage in patients with moderate to severe RA. The analysis examined patients treated with certolizumab pegol plus MTX compared to placebo plus MTX. The data were presented at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, IL (November 5-9, 2011).

"This post-hoc analysis is consistent with previous evidence that suggested an opportunity for healthcare professionals to predict clinical outcomes as early as Week 12 when treating rheumatoid arthritis patients with certolizumab pegol," said Edward Keystone, M.D., The Rebecca MacDonald Center for Arthritis, Mount Sinai Hospital, The University of Toronto. "Moreover, the results indicated that if a patient responds to treatment at 12 Weeks, it may predict disease progression at one year."

Both RAPID3 and EULAR response criteria are measures of disease activity in RA. RAPID3 is an index of three patient self-report measures—physical function, pain, and patient global estimate of status—that can be quickly calculated by a healthcare professional. RAPID3 and its components are seen as markers that may alert a healthcare professional to unanticipated patient problems, provide a baseline measure to support a change in treatment, and numerically document improvement or worsening over time to complement clinical impressions. EULAR response criteria classify individual patien
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
2. Rapid Fire Marketing: Medical Cannabis Management Signs Agreement with Second Non-Profit
3. Baxano Rapidly Expands Sales Force to Support Robust Demand for the iO-Flex® System
4. GNS Healthcare, Inc. Expands Senior Management Team to Leverage the Rapidly Growing Opportunities for Big Data in Healthcare Management
5. Trinity Pharma Solutions Brings SaaS Benefits to Life Sciences Industry with Rapid Access to Actionable Sales Intelligence
6. Scientific Presentations at 2011 AAPM/COMP Meeting Highlight TrueBeam® and RapidArc® Radiotherapy Systems From Varian Medical Systems
7. Researchers Find RapidArc® Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers
8. Al Kindy Hospital in Morocco Carries Out First RapidArc® Radiotherapy Treatments in North Africa
9. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
10. Objet to Demonstrate One-of-a-Kind, Multi-Material 3D Printing Applications at Rapid 2011
11. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015  Imprimis Pharmaceuticals, ... focused on the development and commercialization of proprietary ... will ring The Nasdaq stock market closing bell ... the growing success of its Go Dropless™ campaign ... million cataract procedures are performed annually in the ...
(Date:7/1/2015)... July 1, 2015 Qiming Venture Partners, today ... Managing Partner effective immediately. William has been ... and participated in many Qiming healthcare deals, and assisted ... Chinese market. Qiming, s success in healthcare is not ... distinguished himself with his outstanding advocacy and service mentality ...
(Date:7/1/2015)... Md. , July 1, 2015 ExeGi ... biotherapeutics and probiotic treatments, announced today that it has ... Natural and Non-prescription Health Products Directorate (NNHPD) to sell ... Visbiome was developed by Professor Claudio De ... of extensive clinical investigation. Professor De Simone recently signed ...
Breaking Medicine Technology:Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4Qiming Announces the Promotion of William Hu to Managing Partner 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3
... Feb. 10, 2011 Renaissance Surgical Arts at Newport Harbor ... in the Western United States to offer intraoperative radiotherapy (IORT) ... the TARGIT-A multicenter human clinical trial that demonstrated IORT to ... early breast cancer. IORT has the potential ...
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today ... Financial Officer. Mr. Hoffman, who has accepted a new position in ... until the reporting of the company,s year-end results and the filing ... "We thank Robert for his many years of valuable ...
Cached Medicine Technology:Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 2Renaissance Surgical Arts at Newport Harbor Announces Single-Dose Radiation Treatment Alternative for Women with Early Breast Cancer 3Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer 2Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer 3
(Date:7/1/2015)... , ... July 01, 2015 , ... Convoy of ... community celebration in the Twin Cities on Saturday, August 1, at Spring Lake Park ... community will provide more than $1 million worth of goods and services including free ...
(Date:7/1/2015)... Louisville, KY (PRWEB) , ... July 01, 2015 ... ... Health Care Transformation Task Force, contributing to newly released white paper: “Pro-actively Identifying ... The paper was published July 1st and is available at: http://www.hcttf.org/resouces-tools . ...
(Date:7/1/2015)... Columbus, OH (PRWEB) , ... July 01, 2015 , ... ... pleased to announce Dr. Leslie King has been named Dean of the ... role as Dean, Dr. King will promote and support the vision and mission of ...
(Date:7/1/2015)... Luis Obispo, CA (PRWEB) , ... July 01, ... ... non-surgical bunion treatment, announces their big summer sale. Customers purchasing two or ... with promo code "Summer15". , Bunion Bootie temporarily corrects misaligned toes ...
(Date:7/1/2015)... ... ... B. E. Smith, the only full-service leadership solutions firm dedicated exclusively to ... for Capital Health in Pennington, N.J. One of the top ... more than 1,000 healthcare executives into organizations. , Capital Health is a two-hospital ...
Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:Franklin University Appoints Dean of College of Health & Public Administration 2Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... A team of French surgeons took off on a specially ... attempt the first-ever operation // carried out in weightless ... ,The Airbus A300 is equipped with a special surgical module, ... future surgery carried out in the gravity-free conditions of outer ...
... of patented drugs will play host to a new entrant ... recent communique // by the Director of patent policy in ... arm for the multitude of generic drug manufacturers, who can ... to developing nations. ,Biolyse Pharma Corp., ...
... in the U.S. uncovered the secrets of the deadly Spanish flu ... across the world.// ,The pandemic took lives of ... severity of the virus was not understood then. ,Dr John Kash, ... a research by infecting mice with a reconstructed form of the ...
... Thiruvananthapuram: The Health Department has announced that it ... both prevention as well as // control measures, ... districts in Kerala, Thiruvananthapuram, Alappuzha, Ernakulum and Kozhikode ... of a slackened response by the Health watch ...
... a division that deals with the reconstruction of the ... the occurrence of birth defects like cleft palate. Since ... required. This will not only ensure a smooth operation, ... their face will look like in future., ,In ...
... cornea cells that may also explain how it evades the ... University of Illinois at Chicago College of Medicine. ... Journal of Cell Biology. ,Both strains of the ... on the mouth, and HSV-2, genital herpes -- can infect ...
Cached Medicine News:Health News:Spanish flu virus – secrets uncovere 2Health News:Mathematics And Beauty? You Bet! 2Health News:Herpes Infects Cornea, Evades Immune Cells 2
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... handheld oximeter has been converted to the ... now compatible with the entire line of ... Sensor and SoftCare Nonadhesive Sensors. The redesigned ... Nellcor's latest advanced signal processing technology, which ...
... expanding the growing portfolio of OxiMax® ... is a compact, affordable bedside monitor. ... processing technology, it offers reliable operation ... compatible with the complete family of ...
The Model 900 is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring. It also incorporates an LCD waveform m...
Medicine Products: